Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01UNT
|
|||
Former ID |
DNC000773
|
|||
Drug Name |
ICI 200,880
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
Structure |
Download2D MOL
|
|||
Formula |
C30H34ClF3N4O7S
|
|||
Canonical SMILES |
CC(C)C(C(=O)NC(=O)C1CCCN1C(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Cl
|
|||
InChI |
1S/C30H34ClF3N4O7S/c1-16(2)23(29(43)36-28(42)22-6-5-15-38(22)24(17(3)4)25(39)30(32,33)34)35-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,40)(H,37,41)(H,36,42,43)/t22-,23-,24?/m0/s1
|
|||
InChIKey |
SMCMGLCPSSSOQE-NTZARQNWSA-N
|
|||
CAS Number |
CAS 105080-50-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1], [2] |
KEGG Pathway | Transcriptional misregulation in cancer | |||
Systemic lupus erythematosus | ||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
C-MYB transcription factor network | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
Human Complement System | ||||
Degradation of collagen |
References | Top | |||
---|---|---|---|---|
REF 1 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | |||
REF 2 | Neutrophil elastase inhibitor ICI 200,880 protects against attenuation of coronary flow reserve and myocardial dysfunction following temporary coronary artery occlusion in the dog. Cardiovasc Res. 1994 Jul;28(7):947-56. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.